Independent Folding and Ligand Specificity of the C2 Calciumdependent Lipid Binding Domain of Cytosolic Phospholipase A2*

Eric A. NalefskiDagger , Thomas McDonagh, William Somers, Jasbir Seehra, Joseph J. Falke§, and James D. Clarkpar

From the Small Molecule Drug Discovery Group, Genetics Institute, Inc., Cambridge, Massachusetts 02140 and the § Department of Chemistry and Biochemistry, University of Colorado, Boulder, Colorado 84093

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The Ca2+-dependent lipid binding domain of the 85-kDa cytosolic phospholipase A2 (cPLA2) is a homolog of C2 domains present in protein kinase C, synaptotagmin, and numerous other proteins involved in signal transduction. NH2-terminal fragments of cPLA2 spanning the C2 domain were expressed as inclusion bodies in Escherichia coli, extracted with solvent to remove phospholipids, and refolded to yield a domain capable of binding phospholipid vesicles in a Ca2+-dependent manner. Unlike other C2 domains characterized to date, the cPLA2 C2 domain bound preferentially to vesicles comprised of phosphatidylcholine in response to physiological concentrations of Ca2+. Binding of the cPLA2 C2 domain to vesicles in the presence of excess Ca2+ chelator was induced by high concentrations of salts that promote hydrophobic interactions. Despite the selective hydrolysis of arachidonyl-containing phospholipid vesicles by cPLA2, the cPLA2 C2 domain did not discriminate among phospholipid vesicles containing saturated or unsaturated sn-2 fatty acyl chains. Moreover, the cPLA2 C2 domain bound to phospholipid vesicles containing sn-1 and -2 ether linkages and sphingomyelin at Ca2+ concentrations that caused binding to vesicles containing ester linkages, demonstrating that the carbonyl oxygens of the sn-1 and-2 ester linkage are not critical for binding. These results suggest that the cPLA2 C2 domain interacts primarily with the headgroup of the phospholipid. The cPLA2 C2 domain displayed selectivity among group IIA cations, preferring Ca2+ approximately 50-fold over Sr2+ and nearly 10,000-fold over Ba2+ for vesicle binding. No binding to vesicles was observed in the presence of greater than 10 mM Mg2+. Such strong selectivity for Ca2+ over Mg2+ reinforces the view that C2 domains link second messenger Ca2+ to signal transduction events at the membrane.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Much of the interest in the 85-kDa cytosolic PLA2 (cPLA2)1 stems from its ability to release arachidonic acid from membranes selectively, thus initiating the biosynthesis of prostaglandins, leukotrienes, and platelet-activating factor (for review, see Ref. 1). Maximal activation of cPLA2 in intact cells requires phosphorylation by a member of the mitogen-activated protein kinase family on Ser-505 (2-5). However, in the absence of an increase in cytosolic Ca2+, even stoichiometrically phosphorylated cPLA2 fails to release arachidonic acid because Ca2+ is obligatory for binding to the membrane substrate (3-8). In cells, the increase in Ca2+ results in the selective translocation of cPLA2 to the membranes of the nuclear envelope and endoplasmic reticulum (9-11), resulting in the colocalization of cPLA2 with the downstream enzymes responsible for metabolizing arachidonic acid to prostaglandins and leukotrienes. We have shown previously that the domain responsible for the membrane association is encoded at the NH2 terminus of cPLA2 (6, 7) and serves to bring a Ca2+-independent catalytic domain to the membrane substrate in response to increases in second messenger Ca2+. This Ca2+-dependent lipid binding domain is homologous to the regulatory C2 domain originally described in the classical isoforms of protein kinase C (12) but now recognized to be present in numerous proteins, and it may serve as a paradigm to explain both the features common to these domains as well as those that provide specificity among the domains.

Homologs of the protein kinase C C2 domain have been identified in at least four classes of eukaryotic proteins that carry out critical functions at cellular membranes (1, 6, 13-15). These proteins include lipid-modifying enzymes (e.g. cPLA2, phosphoinositide-specific phospholipase C (PLC), yeast phosphatidylserine decarboxylase-2, several isoforms of the catalytic subunit of phosphatidylinositol 3-kinase, and a plant phospholipase D), protein kinases (e.g. alpha , beta , gamma , delta , epsilon , eta , and theta  isoforms of protein kinase C and certain related protein kinase C), GTPase-activating proteins (ras-GTPase-activating protein and its relatives), and regulators of vesicle transport (e.g. synaptotagmin, rabphilin, DOC2, UNC-13, and perforin). Although the functions of the proteins that contain C2 domains are in many cases well defined, the roles that C2 domains play in these proteins are poorly understood. The generalized function of the C2 domain appears to be membrane association; the ligands for C2 domains identified to date comprise various components of cellular membranes, including phospholipids, inositol polyphosphates, and other membrane-associated proteins (for review in detail, see Ref. 15). Interactions between C2 domains and these ligands are predicted to regulate the various protein-specific biochemical activities. For example, the C2 domain of PLC-delta 1 has been proposed to orient or "fix" the catalytic domain of the enzyme to the membranes after it has been "tethered" by the binding of the pleckstrin homology domain to phosphatidylinositol bisphosphate (16).

To study the ligand specificity of the cPLA2 C2 domain without the effects of lipid binding to the catalytic domain of cPLA2, we have expressed the cPLA2 C2 domain initially as a fusion protein and subsequently as a polypeptide refolded from inclusion bodies free of lipid contamination. This domain binds zwitterionic phospholipid vesicles composed of phosphatidylcholine preferentially over anionic vesicles in the presence of physiological levels of Ca2+. This domain is highly selective for Ca2+ over Sr2+, Ba2+, and Mg2+ with respect to vesicle binding. In addition, this domain binds to phospholipid vesicles lacking sn-1 or -2 carbonyl oxygens and is insensitive to changes in the length and degree of saturation of the sn-2 fatty acyl chain, suggesting that the specific interactions with the ligand are limited to the headgroup of the phospholipid. Based on these results, we compare the properties of the cPLA2 C2 domain with other C2 domains and other proteins that bind phospholipids in a Ca2+-dependent manner.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

DNA Constructions-- Constructions were carried out using conventional protocols (17) to generate DNA encoding proteins that could be expressed in mammalian COS or Chinese hamster ovary (CHO) cells or in Escherichia coli either as fusion proteins with glutathione S-transferase (GST) or as independent polypeptides in inclusion bodies. DNA fragments encoding cPLA2 residues 1-126, 1-138, 1-155, and 1-178 were generated by polymerase chain reaction (PCR) using full-length human cPLA2 cDNA as a template and antisense primers incorporating a 3'-stop codon and EcoRI/SalI restriction sites. For construction of GST fusion proteins, 5'-PCR sense primers incorporated a BglII restriction site, codons for Gly and Ser residues as part of a thrombin cleavage site, and the first seven codons of cPLA2. cPLA2 PCR fragments generated from these PCRs were subcloned into the BamHI/EcoRI polylinker site of the vector pGEX-4T-1 (Pharmacia Biotech Inc.) 3' of the GST gene. Consequently, cPLA2 polypeptides liberated from GST fusion proteins by cleavage with thrombin contain additional NH2-terminal Gly-Ser residues. For construction of cPLA2 polypeptides produced in inclusion bodies, cPLA2 cDNA that had been modified previously by substitution of several 5'-codons with codons preferentially utilized in bacteria served as template DNA for the PCR; 5'-PCR primers incorporated these silent changes and an AflIII restriction site; 3'-PCR primers were the same as those used in GST fusion protein constructions. These PCR products were subcloned into the NcoI/EcoRI sites of the vector pTrcHisB (Invitrogen), removing the 5'-codons encoding the NH2 terminus of the polyHis fusion protein. Consequently, the pTrc constructs reported here utilize the trc promoter and initiator ATG codon normally employed by His fusion proteins, yet they encode cPLA2 residues exclusively when expressed in E. coli. DNA was transformed into the bacterial strain HB101. All DNA constructs were sequenced and shown to be correct. Details of constructions may be obtained from the authors.

Protein Purification-- Bacteria expressing the appropriate constructs were fermented to late log phase and induced with 1 mM isopropyl beta -D-thiogalactopyranoside at 25 °C for GST constructs and 37 °C for inclusion body proteins. For isolation of GST fusion proteins, bacterial cell pellets were lysed by nitrogen cavitation. Supernatant was adsorbed to glutathione-Sepharose beads (Pharmacia), and fusion proteins were removed from beads by cleavage with thrombin (Sigma). Protein was passed over a Mono Q column (Pharmacia) and eluted with approximately 100 mM salt. Protein was dialyzed, concentrated, and stored in buffer (20 mM Tris (pH 7.4), and 0.1 mM EDTA) at 4 °C. Protein was greater than 90% pure, as judged by SDS-PAGE analysis (18). For protein expressed in inclusion bodies, bacterial cell pellets were lysed by microfluidization. Inclusion bodies were harvested, washed, and extracted with chloroform:methanol (2:1) to remove lipids. Inclusion bodies were solubilized in 6 M guanidine HCl (GndHCl), passed over a TSK3000 gel filtration column (Toso-Haas) run in 8 M urea, 20 mM Tris (pH 7.4), 5 mM EDTA, and 5 mM dithiothreitol at room temperature. The appropriate peak was passed over a Mono Q column at room temperature and eluted with 400-500 mM NaCl. Protein was refolded by diluting the desired Mono Q peak into a solution of 0.5 M arginine HCl, 25 mM Tris (pH 8.0), and 5 mM dithiothreitol while stirring slowly at 4 °C. Refolded protein was diluted slowly 2-fold into buffer (25 mM Tris (pH 8.0) and 5 mM dithiothreitol) and again 2-fold into a solution of 2 M (NH4)2SO4, 20 mM Tris (pH 8.0), 5 mM dithiothreitol, and 5 mM EDTA. Refolded protein was adsorbed to a Toyo-phenyl 650S column (Toso-Haas) equilibrated with buffer containing 1 M (NH4)2SO4 and eluted in a single step with salt-free buffer. Eluted protein was concentrated by vacuum dialysis and passed over a Mono Q column. Correctly folded protein eluted with approximately 100 mM NaCl, whereas incorrectly folded protein, as judged by fluorescence spectroscopy (see below), eluted with 400-500 mM NaCl. Correctly folded protein was passed over a phenyl-5PW column (Toso-Haas) and eluted with a linear gradient of decreasing (NH4)2SO4. Correctly folded protein eluted with approximately 100 mM (NH4)2SO4, whereas incorrectly folded protein eluted during the final column wash in salt-free buffer. Protein was concentrated by vacuum dialysis and dialyzed against storage buffer. Protein purity was evaluated by SDS-PAGE on 4-20% and 14% Tris-glycine and 10% Tricine gels (18).

Natural Membrane Binding Assay-- The Ca2+-dependent binding of recombinant proteins to natural membranes isolated from CHO cells was determined as described in detail previously (6, 7). In short, at least 2 µg of test protein was mixed with CHO cell membranes in the presence of 150 mM NaCl, 20 mM HEPES (pH 7.4), and Ca2+/EGTA buffers to maintain the desired free Ca2+ concentration and incubated for 15 min at 30 °C. After centrifugation at 100,000 × g, equal proportions of supernatant and pellet fractions were subjected to SDS-PAGE on 4-20% Tris-glycine gels. Gels were blotted onto nitrocellulose, and test proteins appearing in supernatant and pellet fractions were detected by immunostaining with cPLA2 antisera and visualized by chemiluminescence.

Synthetic Phospholipid Binding Assays-- The binding of the cPLA2 C2 domain, which acts as the fluorescence donor, to small unilamellar phospholipid vesicles containing the fluorescent probe dansylphosphatidylethanolamine (dansyl-PE) (Molecular Probes, Eugene, OR), the fluorescence acceptor, was measured as described previously (7) with modification. A total of 25-50 µg of test protein was diluted into a 2-ml solution containing 60 µg of test liposomes (composed of 5-10% dansyl-PE) in 150 mM NaCl, 20 mM HEPES (pH 7.4), and 1 mM EGTA in 3-ml quartz cuvettes. In experiments comparing different divalent cations, binding reactions were carried out in buffer containing 100 mM KCl, 20 mM HEPES (pH 7.4), and 1 mM EDTA. KCl was diluted from a Ca2+-free Ca2+ electrode-filling solution (Orion Research Incorporated, Boston). Reaction mixtures were stirred continuously, maintained at 20 °C, and illuminated with 284 nm wavelength light; emission of dansyl-PE was recorded at a wavelength of 520 nm. Levels of free divalent cations were raised by the addition of concentrated stocks of cations: for most experiments, a Ca2+ atomic absorption standard (VHG Laboratories, Manchester, NH) was used. Free Ca2+ levels were calculated using the Chelator program (19) taking into account the pH of the binding reactions, measured separately. For experiments testing different divalent cations, the chloride salt of the metal ions (Fluka, puriss grade) was used; free cation levels were calculated according to Raaflaub (20). The fluorescence emission of dansyl-PE in the presence of EGTA or EDTA (I0) was subtracted from that in the presence of added metal ion (I) to determine energy transfer induced by the added metal ion, which was normalized to give (I - I0)/I0, expressed as a percentage. Vesicle compositions were varied according to the experiment. 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (PO-PC), -phosphoethanolamine (PO-PE), -phosphate (PO-PA), -phosphoserine (PO-PS) and -phospho-rac-(1-glycerol) (PO-PG), L-alpha -phosphatidylinositol (mixed acyl-PI), 1-palmitoyl-2-palmitoyl-sn-glycero-3-phosphocholine (PP-PC), 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (PA-PC), 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine (PL-PC), 1,2-di-O-hexadecyl-sn-glycero-3-phosphocholine (as sn-1 and -2 ether-linked phospholipid) and brain sphingomyelin were purchased from Avanti Polar Lipids (Alabaster, AL).

In experiments testing the effect of salt on vesicle binding, reactions were carried out in buffer containing 20 mM HEPES (pH 7.4) and 5 mM EGTA to chelate potential contaminating Ca2+. A solution containing vesicles and protein was reciprocally diluted by a like solution containing concentrated salts to increase the salt concentration and to keep the concentration of vesicles and protein constant. For each salt tested, a parallel series of experiments was carried out using stock solutions free of protein. Fluorescence emission of dansyl-PE in binding reactions free of protein (I0) was subtracted from that containing protein (I) to determine energy transfer due to protein at each salt concentration, which was normalized to give (I - I0)/I0, expressed as a percentage. NaCl, (NH4)2SO4, and NH4Cl were greater than 99.5% pure (Fluka), and Na2SO4 was greater than 99% pure (Aldrich). All salts were specified by the manufacturer to contain less than 0.001% Ca2+.

Binding of the C2 domain to synthetic vesicles was tested additionally as described above for natural membranes with modification. Synthetic phospholipid vesicles were prepared by brief sonication and collected by centrifugation at 100,000 × g. 10 µg of C2 domain was mixed with a 10 mM concentration of the resuspended phospholipid vesicles in the presence of 100 mM KCl, 20 mM PIPES (pH 7.0), and 1 mM EDTA or 1 mM EDTA plus 1.1 mM CaCl2 (to maintain 100 µM free Ca2+) in 100 µl for 5 min at room temperature. After centrifugation, pellet fractions were washed once with reaction buffer and resuspended in buffer containing 0.2% Triton X-100. Equal proportions of supernatant and pellet fractions were subjected to SDS-PAGE on 15% gels. Gels were stained with Coomassie Brilliant Blue R-250, and the amount of protein was quantified by scanning densitometry. Results were expressed as the ratio of the amount of protein present in the pellet fraction to the total amount in pellet and supernatant fractions. Total phosphate analysis of the resuspended vesicles verified that equivalent amounts of PO-PC, -PA, -PS, and -PG and mixed acyl-PI were present in the assay. The amounts of PO-PE which could be collected by centrifugation were very low; therefore, PO-PE was not used in the experiment.

Fluorescence Spectroscopy-- A total of 2 µg of the C2 domain, diluted into a 1-ml solution, with or without denaturant, containing 150 mM NaCl, 20 mM Tris (pH 7.4), and 5 mM EDTA, was excited with 280 nm wavelength light in a 1.5-ml quartz cuvette at room temperature. Fluorescence emission wavelengths were scanned from 300 to 400 nm. Excitation and emission slit widths were both 5 nm. Similar emission maxima (but of lower intensity) were recorded when 294 nm wavelength excitation light was used. For renaturation experiments, a concentrated stock solution of protein prepared in a high concentration of denaturant was serially diluted into buffer without denaturant.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The NH2-terminal 178 residues of cPLA2 (cPLA2(1-178)) contain a C2 domain, a sequence motif that functions as a Ca2+-dependent lipid binding domain (6, 7). Previously, cPLA2(1-178) was expressed as an independent polypeptide in COS cells and bound natural membranes in vitro at Ca2+ concentrations that activated enzymatic activity of cPLA2 (7). In addition, these residues conferred upon a heterologous fusion protein the ability to bind to natural membranes and synthetic phospholipid vesicles in the presence of physiological levels of Ca2+ in vitro (7). We sought to define better the minimal residues of the C2 domain. Based on the structure of the first C2 domain of synaptotagmin (21, 22), the cPLA2 C2 domain was predicted to terminate prior to the exon boundary at Gln-126 (Fig. 1). However, sequence alignment based on the report of a second C2 domain topological fold, that of PLC-delta 1 (16), in which the beta -strand that corresponds topologically to the first beta -strand of synaptotagmin is located at the COOH terminus of the PLC-delta 1 C2 domain, predicted that the cPLA2 C2 domain terminates at the next exon boundary Val-138 (15). Thus, cPLA2 was COOH-terminally truncated at Gln-126 and Val-138, two exon boundaries, to ascertain whether they demarcated minimal functional boundaries. cPLA2 was also truncated in a polar stretch of the polypeptide at Lys-155 to test the importance of residues between 138 and 178. These polypeptides were expressed in COS or CHO cells as independently expressed polypeptides, or they were expressed in E. coli as fusion partners of GST or as inclusion body proteins that could be refolded.


View larger version (0K):
[in this window]
[in a new window]
 
Fig. 1.   Sequence alignment of the cPLA2 C2 domain. The sequence of cPLA2 was aligned with residues from the C2 domains of synaptotagmin I (synI(a)) and PLC-delta 1, which are prototypical of type I and type II C2 topologies (15), respectively. The respective secondary structures of these C2 domains are indicated (16, 21). The letter b above the alignment indicates buried residues in synaptotagmin (21). Boxes indicate positions that coordinate Ca2+ in the first C2 domain of synaptotagmin (21, 22) or coordinate lanthanide ions in PLC-delta 1 (30). Residues highlighted in black denote nonpolar (A, V, M, F, I, L, P, C, or G) or aromatic (F, W, or Y) residues; those highlighted in gray denote polar or charged residues (S, T, N, Q, D, E, K, R, H, W, C, or G) conserved in sequences of 65 distinct C2 domains (15). Below the alignment is a "consensus" sequence for C2 domains which records identical residues present in at least 50% of C2 domains examined (15). Dashes indicate gaps introduced to maximize the alignment. GenBankTM accession numbers are: M72393 (human cPLA2), X52772 (rat synaptotagmin I), and M20637 (rat PLC-delta 1).

Recombinant fragments containing, at a minimum, residues 1-155, were expressed in both COS and CHO cells as soluble polypeptides that bound cellular membranes in a Ca2+-dependent manner (data not shown). In contrast, both cPLA2(1-126) and (1-138) were expressed as insoluble polypeptides in COS cells. We turned to expression of recombinant protein in E. coli, reasoning that expression of cPLA2(1-126) and (1-138) in bacteria grown at lower temperatures in fusion to a highly soluble partner (GST) might overcome the solubility problems associated with protein overexpression in COS cells cultured at 37 °C. Indeed, recombinant fragments containing, at a minimum, residues 1-126 attached to the COOH terminus of GST were expressed as soluble fusion proteins in E. coli. However, GST-cPLA2(1-126) was considerably more insoluble than the other three fusion proteins; the little soluble cPLA2(1-126) that could be liberated from GST-cPLA2(1-126) bound in a Ca2+-independent manner to cellular membranes (data not shown). GST-cPLA2(1-138), (1-155), and (1-178) were fully functional, binding in a Ca2+-dependent manner in vitro to cellular membranes (data not shown). When liberated from GST-fusion proteins by thrombin cleavage and purified, cPLA2(1-138) and (1-155) reversibly bound to phosphatidylcholine vesicles (Fig. 2) and cellular membranes (data not shown) at low micromolar Ca2+ levels. The additional Gly-Ser residues attached to the NH2 terminus of cPLA2(1-138) and (1-155) to create a thrombin cleavage site (see "Experimental Procedures") thus do not hamper binding to phospholipid vesicles. Although cPLA2(1-138) represented the minimal, fully functional C2 domain, we chose to characterize cPLA2(1-155) initially because of its higher yields.


View larger version (0K):
[in this window]
[in a new window]
 
Fig. 2.   Reversible Ca2+-dependent binding of the cPLA2 C2 domain to phospholipid vesicles. cPLA2(1-138) (circles) and cPLA2(1-155) (squares) liberated from GST fusion proteins were incubated with phosphatidylcholine vesicles (90% PP-PC and 10% dansyl-PE) and Ca2+/EGTA buffers to maintain free Ca2+. The change in vesicle fluorescence caused by protein binding (I - I0) was normalized to the starting fluorescence of the vesicle/protein mixture in the presence of 1 mM EGTA (I0) and was plotted as a function of free Ca2+. Fluorescence intensities returned to base line upon addition of excess EGTA (data not shown), demonstrating that the binding is reversible.

cPLA2(1-155) contains several aromatic residues, including a single tryptophan, Trp-71, which serves as a useful spectroscopic probe. Excitation of cPLA2(1-155) at 280 nm resulted in a strong fluorescence emission wavelength maximum at approximately 325 nm (Fig. 3A), which is characteristic of tryptophan buried in a relatively nonpolar environment (23). When diluted into high concentrations of urea or GndHCl, this fluorescence wavelength maximum red-shifted to approximately 348 nm, characteristic of tryptophan exposure to polar solvent. This indicates that Trp-71 of native cPLA2 is buried in a relatively nonpolar environment and that upon denaturation it becomes exposed to solvent. The spectroscopic properties of Trp-71 in cPLA2 are consistent with the location of the homologous residues Phe-206 of synaptotagmin I (21) and Trp-684 of PLC-delta 1 (16), which are buried in the beta 5- and beta 4-strands of type I and II C2 domains, respectively (see Fig. 1). Titration of cPLA2(1-155) with urea or GndHCl revealed a single major transition in unfolding (Fig. 3B). When cPLA2(1-155) was first denatured in urea or GndHCl and then serially diluted into buffer without denaturant, the fluorescence wavelength maximum blue-shifted back to approximately 325 nm (Fig. 3C), revealing that denaturation by these chaotrophic agents is reversible. Further, cPLA2(1-155), which first had been subjected to urea or GndHCl concentrations that denatured the protein then was refolded by 100-fold dilution into buffer without denaturant, exhibited nearly the same Ca2+ dependence for binding to phosphatidylcholine vesicles as native cPLA2(1-155) (Fig. 4). However, it appeared that denaturation and renaturation under these conditions reduced the yield of the protein (see Fig 4. inset).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 3.   Reversible denaturation of the cPLA2 C2 domain monitored by its intrinsic fluorescence. Intrinsic fluorescence of cPLA2(1-155) liberated from GST fusion protein was monitored in the presence of chaotrophic agents. In panel A emission spectra (excitation at 280 nm) of protein diluted in buffer or 8 M urea after buffer subtraction were recorded. Similar results were obtained when tryptophan was excited selectively at 294 nm. In panel B, wavelength maxima of cPLA2(1-155) diluted into increasing concentrations of urea (circles) or GndHCl (squares) were recorded. In panel C are the wavelength maxima of cPLA2(1-155) initially diluted into 10 M urea (circles) or 6 M GndHCl (squares) and subsequently diluted serially into buffer without denaturant to give the indicated concentration of denaturant.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 4.   Function of the cPLA2 C2 domain refolded in vitro. Ca2+-dependent binding of native or refolded cPLA2(1-155) liberated from GST fusion protein to phosphatidylcholine vesicles (95% PO-PC and 5% dansyl-PE) was measured. Protein was diluted initially into buffer (circles) or denatured by diluting into 8 M urea (squares) or 6 M GndHCl (triangles) prior to 100-fold dilution into the vesicle binding reaction. For each sample, the change in vesicle fluorescence caused by protein binding (I - I0) was normalized to the maximal Ca2+-induced fluorescence change (Imax - I0) and plotted as a function of free Ca2+. Data points represent mean of three independent experiments; error bars represent the S.D. In the inset are recorded the maximal fluorescence changes (± S.D. of triplicates) for the three samples at maximal free Ca2+. Upon addition of excess EGTA, fluorescence intensities returned to within <1% of I0 (data not shown).

Given the ability of cPLA2(1-155) derived from GST fusion protein to refold into functional protein, cPLA2(1-126), (1-138), (1-155), and (1-178) were expressed in E. coli inclusion bodies, extracted with a chloroform and methanol mixture (2:1) to remove endogenous lipids, purified, and refolded. Partially purified, refolded cPLA2(1-126) displayed a fluorescence maximum near 331 nm and failed to bind vesicles in response to micromolar levels of Ca2+ (data not shown), suggesting that it had either refolded improperly or that a critical functional portion of the molecule was missing. In contrast, purified refolded cPLA2(1-138) displayed a fluorescence maximum near 325 nm (data not shown), suggesting that cPLA2(1-138) had refolded into a native conformation. cPLA2(1-138) refolded from inclusion bodies bound to natural membranes in a Ca2+-dependent manner (data not shown) and reversibly bound phosphatidylcholine vesicles in a Ca2+-dependent manner (Fig. 5A). The phospholipid binding characteristics of lipid-free preparations of cPLA2(1-138) were characterized in greater detail.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 5.   Reversible Ca2+-dependent binding of cPLA2 C2 domain to vesicles containing select headgroups. Binding of cPLA2(1-138), which was refolded from E. coli inclusion bodies, to vesicles composed of 5% dansyl-PE and 95% zwitterionic or acidic phospholipids as a function of free Ca2+ was measured. Tested in panel A are vesicles composed of PO-PC (circles) and PO-PE (squares). Panel B shows vesicles composed of PO-PA (circles), PO-PS (squares), PO-PG (triangles), and mixed acyl-PI (diamonds). Upon addition of excess EGTA, fluorescence intensities obtained for PO-PC and PO-PE returned to within <1% of I0; for PO-PA fluorescence returned to within 18% of I0 (data not shown). Results are averages of three independent experiments (± S.D.).

To ascertain if the cPLA2 C2 domain interacts directly with the phospholipid headgroup, the binding of the cPLA2 C2 domain to a variety of synthetic vesicles was measured. Reversible binding of cPLA2(1-138) to vesicles containing phosphatidylethanolamine followed the same Ca2+ dependence as binding to phosphatidylcholine; however, the maximal Ca2+-induced fluorescence transfer observed (approximately 10%) was much lower than that observed for phosphatidylcholine (approximately 80%). Because the maximal signal observed for phosphatidylethanolamine could not be increased by increasing the concentration of vesicles (data not shown), the lower maximal signal observed for phosphatidylethanolamine vesicles was likely the result of a lower efficiency of fluorescence resonance energy transfer rather than a lower affinity of C2 domain binding. Differences in the ability of dansyl-PE to pack into the two types of vesicles might account for differences in their ability to accept fluorescence energy from bound proteins. cPLA2(1-138) also bound to vesicles containing phosphatidic acid (Fig. 5B); however, approximately 10-fold greater free Ca2+ was required for half-maximal binding to these vesicles compared with phosphatidylcholine and phosphatidylethanolamine. In addition, because not all of the binding to vesicles containing phosphatidic acid was reversed by EGTA treatment (see legend to Fig. 5), a fraction of the binding observed to these vesicles was Ca2+-independent. No significant Ca2+-dependent binding of cPLA2(1-138) to vesicles containing phosphatidylserine, phosphatidylglycerol, or phosphatidylinositol was observed (Fig. 5B), even at higher vesicle concentrations (data not shown). Thus, the cPLA2 C2 domain displays dramatic selectivity for zwitterionic phospholipid headgroups in the presence of physiological levels of Ca2+.

The phospholipid headgroup selectivity of the cPLA2 C2 domain was confirmed further using a direct binding assay (Fig. 6). In this assay, the cPLA2 C2 domain complexed to phospholipid vesicles was isolated by centrifugation, subjected to SDS-PAGE, and then quantified by staining with Coomassie Brilliant Blue and densitometry. Synthetic vesicles composed of phosphatidylcholine, phosphatidic acid, phosphatidylserine, phosphatidylglycerol, and phosphatidylinositol were tested for their ability to bind to the C2 domain in the presence or absence of Ca2+. We could not test phosphatidylethanolamine vesicles in this manner because PO-PE vesicles could not be collected in comparable yields by centrifugation (see "Experimental Procedures"). As observed by fluorescence resonance energy transfer, the cPLA2 C2 domain bound preferentially to phosphatidylcholine vesicles in a Ca2+-dependent manner. In addition, Ca2+-independent binding to phosphatidic acid vesicles and little or no Ca2+-dependent binding to vesicles composed of phosphatidylserine, phosphatidylglycerol, and phosphatidylinositol were observed.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 6.   Direct Ca2+-dependent binding of cPLA2 C2 domain to vesicles containing select headgroups. Binding of cPLA2(1-138) to pure vesicles composed of the indicated phospholipid vesicles (PO-PC, PO-PA, PO-PS, PO-PG, and mixed acyl-PI) was measured in the presence of EDTA (1 mM; open bars) or 100 µM free Ca2+ (1 mM EDTA plus 1.1 mM CaCl2; filled bars). The percentage of total protein that bound to vesicles after centrifugation was determined by scanning densitometry of supernatant and pellet fractions subjected to SDS-PAGE and visualized by staining with Coomassie Brilliant Blue. Results are averages of three independent experiments (± S.D.).

Because molar concentrations of neutral salts have been shown to promote cPLA2 activity in vitro (24, 25), the ability of several salts to promote vesicle binding by the cPLA2 C2 domain was investigated. High concentrations of Na2SO4 promoted reversible Ca2+-independent binding of cPLA2(1-138) to vesicles containing phosphatidylcholine (Fig. 7). Half-maximal binding was observed above 1 M Na2SO4. High concentrations of (NH4)2SO4 (approximately 2 M) and NaCl (above 3 M) also promoted binding. At greater than 4 M NH4Cl no binding of cPLA2(1-138) was observed. Ca2+-independent binding of the cPLA2 C2 domain to vesicles elicited by these salts did not depend as dramatically on the identity of headgroup of the phospholipid, in contrast to Ca2+-dependent binding (Figs. 5 and 6), since we observed salt-induced binding to vesicles containing phosphatidylethanolamine, phosphatidic acid, phosphatidylserine, phosphatidylglycerol, and phosphatidylinositol (data not shown). These results demonstrate that phospholipid vesicles containing phosphatidylserine, phosphatidylglycerol, and phosphatidylinositol are capable of acting as fluorescence acceptors for cPLA2(1-138) and serve as controls for the Ca2+-induced vesicle binding assay described above. However, vesicles containing phosphatidylcholine displayed significantly better binding at lower salt concentrations and greater efficiency of fluorescence energy transfer at saturating salt concentrations compared with vesicles composed of these other phospholipids.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 7.   Reversible Ca2+-independent binding of the cPLA2 C2 domain to vesicles induced by salts. Binding of cPLA2(1-138) to phosphatidylcholine vesicles (95% PO-PC and 5% dansyl-PE) as a function of Na2SO4 (circles), (NH4)2SO4 (squares), NaCl (triangles), and NH4Cl (diamonds) was measured in the presence of 5 mM EGTA. The increase in vesicle fluorescence caused by protein binding (I - I0) was normalized to vesicle fluorescence in the absence of protein (I0). Results are averages of three independent experiments (± S.D.).

Since cPLA2 cleaves the unsaturated arachidonoyl sn-2 chain (20:4) at least 20-fold more efficiently than the shorter saturated palmitoyl chain (16:0) (6, 26, 27), the dependence of C2 domain activity on length and degree of saturation of the fatty acyl chain was tested. In contrast to the headgroup selectivity noted above, cPLA2(1-138) reversibly bound to phosphatidylcholine vesicles containing sn-2 oleoyl (18:1), linoleoyl (18:2), arachidonoyl (20:4), and palmitoyl (16:0) chains, exhibiting similar Ca2+ dependences (Fig. 8). The weaker maximal fluorescence signals obtained for PA-PC and PP-PC were likely caused by a lower efficiency of energy transfer rather than a lower affinity for binding, since an increase in vesicle concentration had no effect (data not shown). Therefore, the cPLA2 C2 domain does not display selectivity for the structure of the sn-2 acyl chain in Ca2+-dependent binding to phosphatidylcholine.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 8.   Reversible Ca2+-dependent binding of the cPLA2 C2 domain to vesicles containing different sn-2 acyl chains. Binding of cPLA2(1-138) to phosphatidylcholine vesicles (95% PC and 5% dansyl-PE) containing different sn-2 acyl chains as a function of free Ca2+ was measured. Vesicles contained sn-1 palmitoyl and sn-2 oleoyl (18:1) (PO-PC, circles), linoleoyl (18:2) (PL-PC, squares), arachidonoyl (20:4) (PA-PC, triangles), and palmitoyl (16:0) (PP-PC, diamonds). Upon addition of excess EGTA, fluorescence intensities observed for each vesicle solution returned to within <1% of I0 (data not shown). Results are averages of three independent experiments (± S.D.).

Given that the ternary Ca2+-phospholipid-protein complex observed in crystal structures of the low molecular weight secreted by PLA2 show a direct interaction between the sn-2 carbonyl and Ca2+ (28, 29), the effect of altering the linkages between the glycerol backbone and the fatty acyl chain was probed. cPLA2(1-138) reversibly bound in a Ca2+-dependent manner to vesicles composed of brain sphingomyelin (Fig. 9), which contains an amide linkage at the sn-2-like position and a free hydroxyl at the sn-1 position. cPLA2(1-138) also bound reversibly in a Ca2+-dependent manner to vesicles composed of phospholipids containing ether linkages in place of ester linkages at the sn-1 and -2 position (Fig. 9). The same Ca2+ dependence was observed for the binding of cPLA2(1-138) to vesicles composed of sphingomyelin or glycerophospholipids bearing ester or ether linkages; however, the maximal signal obtained for sphingomyelin was not as great as that for the ester- or ether-linked phospholipids, possibly because of lower energy transfer efficiency. Thus, the sn-1 and sn-2 carbonyl oxygens are not critical for Ca2+-dependent binding of the cPLA2 C2 domain to phospholipid vesicles.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 9.   Reversible Ca2+-dependent binding of the cPLA2 C2 domain to sphingomyelin or vesicles containing ester or ether linkages. Binding of cPLA2(1-138) to vesicles composed of 95% sphingomyelin (triangles) or 95% ester-linked PP-PC (circles) or ether-linked PP-PC (squares) and 5% dansyl-PE as a function of free Ca2+ was measured. Upon addition of excess EGTA, fluorescence intensities returned to within <3% of I0 (data not shown). Results are averages of three independent experiments (± S.D.).

To ascertain the cation selectivity of the cPLA2 C2 domain, vesicle binding was tested in the presence of various divalent metals. cPLA2(1-138) bound to phosphatidylcholine vesicles in the presence of Ca2+, Sr2+, and Ba2+; this binding was reversible upon cation chelation (Fig. 10). However, approximately 50-fold greater concentration of Sr2+ and nearly 10,000-fold greater Ba2+ over Ca2+ was required for half-maximal binding (Fig. 10). No significant binding to vesicles was observed in the presence of greater than 10 mM Mg2+. Therefore, the cPLA2 C2 domain displays at least 10,000-fold selectivity for Ca2+ over the other physiological cation Mg2+ in binding to phosphatidylcholine.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 10.   Reversible binding of the cPLA2 C2 domain to vesicles induced by select divalent cations. Binding of cPLA2(1-138) to phosphatidylcholine vesicles (95% PO-PC and 5% dansyl-PE) as a function of free Ca2+ (circles), Sr2+ (squares), Ba2+ (triangles), or Mg2+ (diamonds) was measured. Free metal levels were maintained using metal salts/EDTA buffers and were increased by the addition of concentrated stocks of metal salts. Upon addition of excess EDTA, fluorescence intensities obtained in Ca2+ and Sr2+ titrations returned to within <2% of I0; for Ba2+ titrations, they returned to within <7% of I0 (data not shown). Results are averages of three independent experiments (±S.D.).

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

In this report we characterize cPLA2(1-138) as a minimal NH2-terminal fragment of cPLA2 that functions as a Ca2+-dependent lipid binding domain. Interestingly, Val-138 corresponds to the end of a short exon that begins with Val-127 (1, 6). Shortening this domain to the next nearest COOH-terminal exon boundary (after Gln-126) produced a polypeptide that is likely to be folded improperly when expressed in E. coli for the following reasons: (a) a greater fraction of GST-cPLA2(1-126) was expressed as insoluble material in E. coli compared with other GST-C2 domain fusion proteins; (b) when liberated from the limited GST fusion protein that could be isolated, cPLA2(1-126) bound CHO cell membranes in a Ca2+-independent manner; (c) cPLA2(1-126) refolded from inclusion bodies failed to bind to vesicles in response to Ca2+ or high concentrations of NA2SO4 (data not shown). These results support the hypothesis that the cPLA2 C2 domain forms the alternative type II C2 domain topology represented by PLC-delta 1 (16, 30), which was predicted by sequence alignment (15).

The metal-dependent phospholipid binding of the cPLA2 C2 domain displays selectivity among group IIA cations in the order of preference Ca2+ > Sr2+ > Ba2+ > Mg2+. Notably, the same preference was observed for hydrolysis of phospholipid vesicles by the full-length cPLA2 (24, 31). The pattern of metal-selective vesicle binding by the cPLA2 C2 domain is identical to that observed for the binding of the first C2 domains of synaptotagmin to phosphatidylserine vesicles (32, 33). The cation selectivity of rabphilin has not been reported in detail; however, under the assay conditions reported, Ca2+, but not Ba2+, Sr2+, or Mg2+, promoted phospholipid binding (34). Because Ca2+ is the sole metal capable of promoting membrane binding at physiological concentrations, these C2 domains must possess metal ion binding sites optimized for divalent ions the size of Ca2+, as has been observed in other Ca2+ binding sites that exclude Mg2+ (35). As observed for phospholipid binding by the synaptotagmin C2 domain (32, 33, 36), vesicle binding by the cPLA2 C2 domain induced by Ca2+ is positively cooperative, suggesting the presence of multiple Ca2+ ions in the phospholipid·Ca2+·C2 domain ternary complex. This finding is consistent with NMR and crystallographic studies of the C2 domains of synaptotagmin and PLC-delta 1, which support the presence of multiple Ca2+ binding sites (16, 20, 21, 30).

The phospholipid preference of the cPLA2 C2 domain is distinct from that described for isolated C2 domains of other proteins characterized to date. Whereas C2 domains of most synaptotagmins, rabphilin, DOC2 (and full-length protein kinase C-beta ) require the presence of anionic but not zwitterionic phospholipid in vesicles for binding (7, 32, 34, 36-38), at physiological ionic strength and Ca2+, the cPLA2 C2 domain binds preferentially to vesicles comprised of phosphatidylcholine. It is worth noting that the residues separating the aspartates in the second Ca2+ binding loop (the loop between strands beta 6 and beta 7 in type I C2 domains) of synaptotagmin, rabphilin, DOC2, and protein kinase C-beta contain positively charged residues, whereas the corresponding short stretch in cPLA2 (the loop between strands beta 5 and beta 6 in type II C2 domains) contains hydrophobic residues (see Fig. 1). In addition, in place of the histidine immediately preceding the last Ca2+ coordinating residue in synaptotagmin, the C2 domain of cPLA2 contains an aspartate. Perhaps the choline headgroup interacts with these acidic and hydrophobic residues in this loop of cPLA2 but is repelled by the basic residues of C2 domains which interact with anionic vesicles. Interestingly, the C2 domain of cPLA2 binds to vesicles containing the small anionic headgroup phosphate of phosphatidic acid to some extent at high Ca2+ concentrations.

To date, little information has been published addressing the critical interactions between the phospholipid and C2 domains. Because we were able to refold the cPLA2 C2 domain from inclusion bodies, we had the opportunity to extract first any endogenous lipids that might have compromised our studies. The preference of the cPLA2 C2 domain for the neutral headgroup phosphocholine contrasts sharply with the headgroup preference at the active site of cPLA2 where less than 4-fold selectivity has been observed among phosphocholine, phosphoethanolamine, phosphate, phosphoserine, and phosphoinositol, despite their large structural differences (26, 27). Because phosphatidylmethanol was used to trap cPLA2 in these experiments, it is noteworthy that we have observed Ca2+-dependent binding of the cPLA2 C2 domain to vesicles containing this nonphysiological headgroup (data not shown).

The lack of selectivity for the sn-2 acyl chain in vesicle binding by the cPLA2 C2 domain is strikingly different from the selectivity observed in liposome hydrolysis by the full-length enzyme. The cPLA2 C2 domain does not distinguish among acyl chains in the sn-2 position, whereas the catalytic center prefers the unsaturated arachidonoyl (20:4) chain by 20-40-fold over the saturated palmitoyl (18:0) chain (6, 26, 27, 39-43).

We have also demonstrated that vesicle binding by the cPLA2 C2 domain does not require the carbonyl oxygens of the ester linkage at either the sn-1 or -2 positions by showing equivalent binding to either natural diacylphosphatidylcholine or synthetic phosphatidylcholine containing ether linkages at the sn-1 and -2 positions. We also showed that the cPLA2 C2 domain binds to sphingomyelin, which contains an amide linkage at the sn-2-like position. Together these results indicate that the C2 domain does not coordinate Ca2+ via the sn-2 carbonyl oxygen. Similarly, acyl linkages are not required for the binding of annexin V to phospholipid vesicles in the presence of Ca2+; in the crystal structure of annexin V bound to Ca2+ and a phospholipid analog, Ca2+ was coordinated via an sn-3 phosphoryl oxygen (44). In contrast, the sn-2 carbonyl oxygen (in conjunction with an sn-3 phosphoryl oxygen) coordinates Ca2+ when bound to the structurally and mechanistically dissimilar secreted PLA2 (28, 29).

Our results indicate that hydrolysis of phospholipid vesicles by cPLA2 induced by high salt concentrations in the absence of Ca2+ as observed previously (24, 25) is likely due to salt-induced Ca2+-independent phospholipid binding by its C2 domain and Ca2+-independent hydrolysis of the substrate. We observed previously that a recombinant cPLA2 lacking the C2 domain failed to hydrolyze phospholipid vesicles in the presence of high concentrations of salt, even though this protein hydrolyzed monomeric substrates at wild type rates in the absence of Ca2+ (7). We show here that the C2 domain of cPLA2 binds to phospholipid vesicles in the absence of Ca2+ when subjected to high concentrations of select salts. The extreme steepness of the binding curves as a function of salt concentration and potency in the molar range suggest that salt-induced phospholipid binding results from the effects of multiple ionic interactions with the protein or solvent (or vesicle) rather than substitution of a cation for Ca2+ in the metal binding site. These salts are likely to stabilize a hydrophobic interface of the C2 domain because the relative potency of these ions (Na+ > NH4+; SO4-2 > Cl-) follows exactly the Hofmeister series of cations and anions that promote hydrophobic interactions (45). This hydrophobic interface may also be stabilized by Ca2+ binding to the C2 domain and might interact directly with a hydrophobic portion of the phospholipid vesicle or form an allosteric switch to induce vesicle binding elsewhere in the C2 domain. C2 domains that bind phospholipids in a Ca2+-independent manner may have evolved to stabilize this interface constitutively.

Our experiments have not addressed the reason why full-length cPLA2 translocates selectively to the nuclear and endoplasmic reticulum membranes over plasma membranes (9-11, 46) or even if this preference is encoded within the C2 domain. The preference may be caused by interaction of cPLA2 with a docking protein localized to the these membranes, or it may be the result of differences in the composition of membranes. For example, cPLA2 may translocate to these membranes selectively over the plasma membrane because the latter contains high levels of sphingomyelin and cholesterol, both of which promote order and tight packing of phospholipids. Nevertheless, the cPLA2 C2 domain was shown to bind with high affinity to the vesicles composed of sphingomyelin. Similarly, in experiments not shown, we have observed that high levels of cholesterol also do not block binding to the membrane. Interestingly, sphingomyelin has been reported to inhibit a partially purified cPLA2 (47). This result, together with the finding that full-length cPLA2 binds more tightly to membranes containing products of phospholipid hydrolysis (31), suggests that sphingomyelin content may influence binding, not by blocking the initial binding event but by inhibiting the PLA2 reaction that promotes increased binding.

In conclusion, we have demonstrated that the first 138 amino acids of cPLA2, ending at an exon border, constitute a minimal NH2-terminal fragment of cPLA2 which contains a fully active C2 domain. This finding suggests that the cPLA2 C2 domain possesses a topology similar to the C2 domain of PLC-delta 1 rather than that of the first synaptotagmin C2 domain. By observing a selectivity among headgoups and yet no preference in the fatty acyl chains or the linkages to the glycerol backbone, we have also determined the portions of the phospholipid which are likely to intimately contact the C2 domain. Finally, we have demonstrated that Ca2+ is the only divalent metal that promotes binding at physiological concentrations, thus reinforcing the concept that the cPLA2 C2 domain and the Ca2+-dependent C2 domains in general link second messenger Ca2+ to protein function.

    ACKNOWLEDGEMENTS

We thank Dale Cumming for advice, Neil Schauer for large scale bacterial fermentation, Elliott Nickbarg for mass spectroscopic analysis, and John Knopf for continuing support and advice.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by National Institutes of Health Postdoctoral Fellowship GM 18303. Present address: Dept. of Chemistry and Biochemistry, University of Colorado at Boulder, Boulder, CO 84093.

Supported by National Institutes of Health Grant 48203.

par To whom correspondence should be addressed: Small Molecule Drug Discovery Group, Genetics Institute, Inc., 87 Cambridge Park Dr., Cambridge, MA 02140. Tel.: 617-498-8944; Fax: 617-498-8993.

1 The abbreviations used are: cPLA2, cytosolic phospholipase A2; C2, second conserved; PLC, phospholipase C; CHO, Chinese hamster ovary; GST, glutathione S-transferase; PCR, polymerase chain reaction; PAGE, polyacrylamide gel electrophoresis; GndHCl, guanidine hydrochloride; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; dansyl-PE, N-(5-dimethylaminonaphthalene-1-sulfonyl)-1-palmitoyl-2-palmitoyl-sn-glycero-3-phosphoethanolamine; PO-PC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; PO-PE, -phosphoethanolamine; PO-PA, -phosphate; PO-PS, -phosphoserine; -PG, phospho-rac-(1-glycerol); mixed acyl-PI, phosphatidylinositol containing a mixture of acyl chains; PP-PC, 1-palmitoyl-2-palmitoyl-sn-glycero-3-phosphocholine; PA-PC, 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine; PL-PC, 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine; sn-1 and -2 ether-linked phospholipid, 1,2-di-O-hexadecyl-sn-glycero-3-phosphocholine; PIPES, 1,4-piperazinediethanesulfonic acid.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Clark, J. D., Schievella, A. R., Nalefski, E. A., Lin, L.-L. (1995) J. Lipid Mediators Cell Signalling 12, 83-118[CrossRef][Medline] [Order article via Infotrieve]
  2. Lin, L.-L., Lin, A. Y., and Knopf, J. L. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 6147-6151[Abstract]
  3. Lin, L.-L., Wartmann, M., Lin, A. Y., Knopf, J. L., Seth, A., Davis, R. J. (1993) Cell 72, 269-278[Medline] [Order article via Infotrieve]
  4. Kramer, R. M., Roberts, E. F., Strifler, B. A., Johnstone, E. M. (1995) J. Biol. Chem. 270, 27395-27398[Abstract/Free Full Text]
  5. Qui, Z. H., and Leslie, C. C. (1994) J. Biol. Chem. 269, 19480-19487[Abstract/Free Full Text]
  6. Clark, J. D., Lin, L.-L., Kriz, R. W., Ramesha, C. S., Sultzman, L. A., Lin, A. Y., Milona, N., Knopf, J. L. (1991) Cell 65, 1043-1051[Medline] [Order article via Infotrieve]
  7. Nalefski, E. A., Sultzman, L. A., Martin, D. M., Kriz, R. W., Towler, P. S., Knopf, J. L., Clark, J. D. (1994) J. Biol. Chem. 269, 18239-18249[Abstract/Free Full Text]
  8. Channon, J. Y., and Leslie, C. C. (1990) J. Biol. Chem. 265, 5409-5413[Abstract/Free Full Text]
  9. Peters-Golden, M., and McNish, R. W. (1993) Biochem. Biophys. Res. Commun. 196, 147-153[CrossRef][Medline] [Order article via Infotrieve]
  10. Glover, S., Bayburt, T., Jonas, M., Chi, E., and Gelb, M. H. (1995) J. Biol. Chem. 270, 15359-15367[Abstract/Free Full Text]
  11. Schievella, A., Regier, M. K., Smith, W. L., Lin, L.-L. (1995) J. Biol. Chem. 270, 30749-30754[Abstract/Free Full Text]
  12. Coussens, L., Parker, P. J., Rhee, L., Yang-Feng, T. L., Chen, E., Waterfield, M. D., Franke, U., Ullrich, A. (1986) Science 233, 859-866[Medline] [Order article via Infotrieve]
  13. Brose, N., Hofmann, K., Hata, Y., and Südhof, T. C. (1995) J. Biol. Chem. 270, 25273-25280[Abstract/Free Full Text]
  14. Ponting, C. P., and Parker, P. J. (1996) Protein Sci. 5, 162-166[Abstract/Free Full Text]
  15. Nalefski, E. A., and Falke, J. J. (1996) Protein Sci. 5, 2375-2390[Abstract/Free Full Text]
  16. Essen, L.-O., Perisic, O., Katan, M., and Williams, R. L. (1996) Nature 380, 595-602[CrossRef][Medline] [Order article via Infotrieve]
  17. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  18. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
  19. Schoenmakers, T. J. M., Visser, G. J., Flik, G., Theuvenet, A. P. R. (1992) BioTechniques 12, 870-879 [Medline] [Order article via Infotrieve]
  20. Raaflaub, J. (1960) Methods Biochem. Anal. 3, 301-325
  21. Sutton, R. B., Davletov, B. A., Berghuis, A. M., Südhof, T. C., Sprang, S. R. (1995) Cell 80, 929-938[Medline] [Order article via Infotrieve]
  22. Shao, X., Davletov, B. A., Sutton, R. B., Südhof, T. C., Rizo, J. (1996) Science 273, 248-251[Abstract]
  23. Lakowicz, J. R. (1986) Principles of Fluorescence Spectroscopy, pp. 345-350, Plenum Press, New York
  24. Reynolds, L. J., Hughes, L. L., Louis, A. I., Kramer, R. M., Dennis, E. A. (1993) Biochim. Biophys. Acta 1167, 272-280[Medline] [Order article via Infotrieve]
  25. Wijkander, J., and Sundler, R. (1992) Biochem. Biophys. Res. Commun. 184, 118-124[Medline] [Order article via Infotrieve]
  26. Diez, E., Louis-Flamberg, R., Hall, R. H., Mayer, R. J. (1992) J. Biol. Chem. 267, 18342-18348[Abstract/Free Full Text]
  27. Hanel, A. M., Schüttel, S., and Gelb, M. H. (1993) Biochemistry 32, 5949-5958[Medline] [Order article via Infotrieve]
  28. Thunnissen, M. M. G. M., AB, E., Kalk, K. H., Drenth, J., Dijkstra, B. W., Kuipers, O. P., Dijkman, R., de Haas, G. H., Verheij, H. M. (1990) Nature 347, 689-691[CrossRef][Medline] [Order article via Infotrieve]
  29. Scott, D. L., White, S. P., Otwinowski, Z., Yuan, W., Gelb, M. H., Sigler, P. B. (1990) Science 250, 1541-1546[Medline] [Order article via Infotrieve]
  30. Grobler, J. A., Essen, L.-O., Williams, R. L., Hurley, J. H. (1996) Nat. Struct. Biol. 3, 788-795[Medline] [Order article via Infotrieve]
  31. Ghomashchi, F., Schüttel, S., Jain, M. K., Gelb, M. H. (1992) Biochemistry 31, 3814-3824[Medline] [Order article via Infotrieve]
  32. Davletov, B. A., and Südhof, T. C. (1993) J. Biol. Chem. 268, 26386-26390[Abstract/Free Full Text]
  33. Li, C., Davletov, B. A., and Südhof, T. C. (1995) J. Biol. Chem. 270, 24898-24902[Abstract/Free Full Text]
  34. Yamaguchi, T., Shiritaki, H., Kishida, S., Miyazaki, M., Nishikawa, J., Wada, K., Numata, S., Kaibuchi, K., and Takai, Y. (1993) J. Biol. Chem. 268, 27164-27170[Abstract/Free Full Text]
  35. Falke, J. J., Drake, S. K., Hazard, A. L., Peersen, O. B. (1994) Q. Rev. Biophys. 27, 219-290[Medline] [Order article via Infotrieve]
  36. Fukuda, M., Kojima, T., and Mikoshiba, K. (1996) J. Biol. Chem. 271, 8430-8434[Abstract/Free Full Text]
  37. Li, C., Ullrich, B., Zhang, J. Z., Anderson, R. G. W., Brose, N., Südhof, T. C. (1995) Nature 375, 594-599[CrossRef][Medline] [Order article via Infotrieve]
  38. Orita, S., Sasaki, T., Naito, A., Komura, R., Ohtsuka, T., Maeda, M., Suzuki, H., Igarashi, H., and Takai, Y. (1995) Biochem. Biophys. Res. Commun. 206, 439-448[CrossRef][Medline] [Order article via Infotrieve]
  39. Leslie, C. C. (1991) J. Biol. Chem. 266, 11366-11371[Abstract/Free Full Text]
  40. Gronich, J. H., Bonventre, J. V., and Nemonoff, R. A. (1990) Biochem. J. 271, 37-43[Medline] [Order article via Infotrieve]
  41. Kramer, R. M., Roberts, E. F., Manetta, J., and Putnam, J. E. (1991) J. Biol. Chem. 266, 5268-5272[Abstract/Free Full Text]
  42. Takayama, K., Kudo, L., Kim, D. K., Nagata, K., Nozawa, T., Inoue, K. (1991) FEBS Lett. 282, 326-330[CrossRef][Medline] [Order article via Infotrieve]
  43. Wijkander, J., and Sundler, R. (1991) Eur. J. Biochem. 202, 873-880[Abstract]
  44. Swairjo, M. A., Concha, N. O., Kaetzel, M. A., Dedman, J. R., Seaton, B. A. (1995) Nat. Struct. Biol. 2, 968-974[Medline] [Order article via Infotrieve]
  45. Creighton, T. E. (1993) Proteins, Structures and Molecular Principles, 2nd Ed., p. 156, W. H. Freeman and Company, New York
  46. Sierra-Honigmann, M. R., Bradley, J. R., Pober, J. S. (1996) Lab. Invest. 74, 684-695[Medline] [Order article via Infotrieve]
  47. Leslie, C. C., and Channon, J. Y. (1990) Biochim. Biophys. Acta 1045, 261-270[Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.